CompletedNot Applicable

Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

United States14 participantsStarted 2018-06-15

Plain-language summary

This trial studies how well standard and delayed fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) given after standard radiation and chemotherapy works in assessing patients with head and neck squamous cell cancer that has spread to other places in the body. Diagnostic procedures, such as PET/CT, use radioactive material, such as fludeoxyglucose F-18, to find and diagnose head and neck tumors and may help to find out how far the disease has spread.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult with computed tomography (CT) or fludeoxyglucose F-18 (FDG) positron emission tomography (PET) findings of cervical nodal metastasis from a head and neck primary squamous cell carcinoma treated with definitive chemoradiation Exclusion Criteria: * Children * No evidence of cervical nodal metastasis * Active infection of the head and neck * Known allergy to FDG, iodine or gadolinium-based contrast agents * Blood glucose (\> 250 mg/dl) * Pregnant women

What they're measuring

Optimal imaging time

Timeframe: Up to 6 months

Differences in L/B ratio

Timeframe: Up to 6 months

Trial details

NCT IDNCT03575949

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-10

View on ClinicalTrials.gov More Metastatic Head and Neck Squamous Cell Carcinoma trials